|Mr. Lonnel Coats||Pres, CEO & Director||1,12M||N/A||1965|
|Mr. Jeffrey L. Wade||Exec. VP of Corp. & Admin. Affairs and CFO||638,36k||N/A||1965|
|Dr. Pablo Lapuerta||Exec. VP & Chief Medical Officer||570,92k||N/A||1963|
|Dr. Praveen Tyle||Exec. VP of R&D||679,65k||N/A||1960|
|Mr. Alexander A. Santini||Exec. VP & Chief Commercial Officer||588,27k||N/A||1959|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 9. Dezember 2019, lautet 9. Die grundlegenden Scores sind Audit: 5, Vorstand: 9, Shareholderrechte: 7, Kompensation: 8.